Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Linda A Pestano"'
Autor:
D. Lynn Kirkpatrick, Cari Evans, Linda A. Pestano, Jeffrey Millard, Matthew Johnston, Emily Mick, William K. Schmidt
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 3, Pp n/a-n/a (2024)
Abstract PF614, a trypsin‐activated abuse protection oxycodone prodrug designed to reduce recreational drug abuse, was compared to OxyContin for safety and pharmacokinetics (PKs) of plasma oxycodone following oral administration. This study was a t
Externí odkaz:
https://doaj.org/article/ff177eccb53f41dfa9ae01919fad64a1
Autor:
Aimee L. Jackson, Pankaj Trivedi, David Avigan, Linda A Pestano, Diana Escolar, Xuan Beatty, Anita G. Seto, Eleni Anastasiadou, Melanie Hermreck, Maud-Emmanuelle Gilles, Dina Stroopinsky, Frank J. Slack, Cinzia Marchese, Lauren C. Pinter-Brown
Publikováno v:
Clinical Cancer Research. 27:1139-1149
Purpose: miRNA-155 is an oncogenic miRNA highly expressed in B-cell malignancies, particularly in the non–germinal center B-cell or activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL), where it is considered a potential diagnostic
Autor:
Aimee L. Jackson, Brent A Dickinson, Corrie L. Gallant-Behm, Christina Dalby, Joseph Piper, Linda A Pestano
Publikováno v:
Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. 26(4)
There is a strong unmet need for new therapeutics to accelerate wound healing across both chronic and acute indications. It is well established that local tissue hypoxia, vascular insufficiency, and/or insufficient angiogenesis contribute to inadequa
Autor:
Anita G. Seto, Thomas A. Mustoe, Seok Jong Hong, William Marshall, Paul Rubin, Aimee L. Jackson, Linda A Pestano, Corrie L. Gallant-Behm, Catherine Maari, Joshua M. Lynch, Christina Dalby, Joseph Piper
Publikováno v:
The Journal of investigative dermatology. 139(5)
MicroRNA-29 (miR-29) negatively regulates fibrosis and is downregulated in multiple fibrotic organs and tissues, including in the skin. miR-29 mimics prevent pulmonary fibrosis in mouse models but have not previously been tested in the skin. This stu
Autor:
William Marshall, R.C. Rodgers, A.M. James, R.D. Hopkins, Linda A Pestano, Paul Rubin, J. Ruckman, D. Escolar
Publikováno v:
Hematological Oncology. 37:562-563
Autor:
Rusty L. Montgomery, Linda A Pestano, Catherine Nicholas, Guoying Yu, Farida Ahangari, Naftali Kaminski, Jacob D. McDonald, Philip J. Kuehl, Jeremy Brower, Christina Dalby, Jose D. Herazo-Maya, Brent A Dickinson, Corrie L. Gallant-Behm
Publikováno v:
Mechanisms of Lung Injury and Repair.
miRNA-29 targets multiple profibrotic molecules and is down-regulated during organ fibrosis, including IPF. Previously, we showed a synthetic, chemically stabilized oligonucleotide mimic of miR-29b could repress collagen expression and abrogate pulmo
Autor:
Theresa R. Pacheco, Francine M. Foss, Bradley M. Haverkos, Gilad Gordon, Ioanna Cheronis, William Marshall, Jennifer DeSimone, Auris Huen, Joan Guitart, Paul Rubin, Herbert Eradat, Paul J. Williams, Kristin Schroeder, Diana Escolar, Lauren C. Pinter-Brown, Linda A Pestano, Basem M. William, Pierluigi Porcu, Ahmad Halwani, Christiane Querfeld, Youn H. Kim
Publikováno v:
Blood. 132:2903-2903
Background: Cobomarsen (MRG-106) is an inhibitor of miR-155, a microRNA with a strong link to cutaneous T cell lymphoma (CTCL) pathogenesis. The goals of this first in human study are to evaluate the safety, tolerability, pharmacokinetics, and effica
Autor:
Youn H. Kim, Herbert Eradat, Pierluigi Porcu, Christiane Querfeld, Jennifer DeSimone, Paul Rubin, Auris Huen, Lauren Pinter-Brown, Francine M. Foss, Gilad Gordon, Jud Williams, Linda A Pestano, Joan Guitart, Anita G. Seto, William Marshall, Diana Escolar, Basem M. William, Ahmad Halwani, Theresa R. Pacheco, Bradley M. Haverkos
Publikováno v:
Journal of Clinical Oncology. 36:2511-2511
2511Background: MRG-106 is an inhibitor of miR-155, a microRNA with a strong link to CTCL pathogenesis. The goals of this FIH study are to evaluate the safety, tolerability, PK, and efficacy of MRG...
Autor:
Gilad Gordon, Theresa R. Pacheco, Brent A Dickinson, Joan Guitart, Bradley M. Haverkos, Basem M. William, Aimee L. Jackson, Linda A Pestano, Jennifer DeSimone, Judy Ruckman, Ahmad Halwani, Paul J. Williams, Bill S Marshall, Youn H. Kim, Anita G. Seto, Christiane Querfeld, Lauren C. Pinter-Brown, Pierluigi Porcu, Francine M. Foss, Paul Rubin
Publikováno v:
Blood. 130:820-820
Introduction & Objectives: MRG-106 is an oligonucleotide inhibitor of miR-155, a microRNA with a strong mechanistic link to CTCL. The goals of this first-in-human study are to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary
Autor:
G.G. Gordon, Aimee L. Jackson, J. Ruckman, Catherine Maari, Joshua M. Lynch, B.A. Dickinson, D.M. Rodman, Corrie L. Gallant-Behm, Christina Dalby, M. Sanseverino, M.L. Landry, Paul Rubin, William Marshall, Linda A Pestano, Anita G. Seto
Publikováno v:
Journal of Investigative Dermatology. 137:B4